Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CCNU versus CCNU + dasatinib in recurrent glioblastoma
NL-OMON33494Phase 2Active, not recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Jan 2010
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in glioblastoma (GBM) comparing Lomustine monotherapy with Lomustine + dasatinib (2 arms). Primary endpoint: Progression-free survival at 6 months. Started Jan 2010; status: active, not recruiting.
02
Drugs
lomustinedasatinib
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NL-OMON33494.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON33494.